Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
ACELYRIN, INC. (SLRN)
NASDAQ:SLRN
ACELYRIN, INC. (SLRN) Stock Price & Analysis
94 Followers
SLRN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.14 - $29.88
Previous Close$4.63
Volume742.13K
Average Volume (3M)1.20M
Market Cap
$458.49M
Enterprise Value-$261.64M
Total Cash (Recent Filing)$721.33M
Total Debt (Recent Filing)$1.19M
Price to Earnings (P/E)-1.9
Beta1.40
Next Earnings
Aug 12, 2024EPS Estimate
-$0.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.46
Shares Outstanding99,026,983
10 Day Avg. Volume803,096
30 Day Avg. Volume1,197,894
Standard Deviation0.26
R-Squared0.19
Alpha-0.13
Financial Highlights & Ratios
Price to Book (P/B)0.71
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.88
Forecast
1Y Price Target
$23.80Price Target Upside442.14% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
ACELYRIN, INC. News
PremiumCompany Announcements
ACELYRIN, INC. Appoints Mina Kim as New CEO
Bulls Say, Bears Say
Bulls Say
Drug Development ProgressThe company accelerated the timeline for Phase 3 HS data, suggesting confidence in their enrollment process and study progression.
Financial StrengthThe company has a substantial cash reserve of approximately $680MM, demonstrating a solid financial position for future operations.
Product CompetitivenessInitial Phase 1/2 results for Lonigutamab showed all endpoints were met with comparable or improved rates versus competitors.
Bears Say
Drug EfficacyPrevious Phase 2b/3 HS study did not meet its primary endpoint, raising concerns about the drug's efficacy.
Drug Safety And Market CompetitionRisks include potential safety issues, less-than-expected efficacy results, and competitive market pressures.
Financial HealthThe company may face significant additional financing needs, impacting its financial stability.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
SLRN FAQ
What was ACELYRIN, INC.’s price range in the past 12 months?
ACELYRIN, INC. lowest stock price was $4.14 and its highest was $29.88 in the past 12 months.
What is ACELYRIN, INC.’s market cap?
Currently, no data Available
When is ACELYRIN, INC.’s upcoming earnings report date?
ACELYRIN, INC.’s upcoming earnings report date is Aug 12, 2024 which is in 86 days.
How were ACELYRIN, INC.’s earnings last quarter?
ACELYRIN, INC. released its earnings results on May 13, 2024. The company reported -$0.36 earnings per share for the quarter, beating the consensus estimate of -$0.972 by $0.612.
Is ACELYRIN, INC. overvalued?
According to Wall Street analysts ACELYRIN, INC.’s price is currently Undervalued.
Does ACELYRIN, INC. pay dividends?
ACELYRIN, INC. does not currently pay dividends.
What is ACELYRIN, INC.’s EPS estimate?
ACELYRIN, INC.’s EPS estimate is -$0.9.
How many shares outstanding does ACELYRIN, INC. have?
ACELYRIN, INC. has 99,026,985 shares outstanding.
What happened to ACELYRIN, INC.’s price movement after its last earnings report?
ACELYRIN, INC. reported an EPS of -$0.36 in its last earnings report, beating expectations of -$0.972. Following the earnings report the stock price went up 0.214%.
Which hedge fund is a major shareholder of ACELYRIN, INC.?
Among the largest hedge funds holding ACELYRIN, INC.’s share is Woodline Partners LP. It holds ACELYRIN, INC.’s shares valued at 7M.
---
ACELYRIN, INC. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$23.80 (442.14% Upside)
$23.80 (442.14% Upside)
Blogger Sentiment
Bullish
SLRN Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $185.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.4%
Last 30 Days ▲ 3.7%
Last 30 Days ▲ 3.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-77.65%
12-Months-Change
Fundamentals
Return on Equity
-53.53%
Trailing 12-Months
Asset Growth
133.65%
Trailing 12-Months
Company Description
ACELYRIN, INC.
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California.
---
SLRN Earnings Call
Q3 2023
0:00 / 0:00
---
SLRN Stock 12 Month Forecast
Average Price Target
$23.80
▲(442.14% Upside)
Technical Analysis
Best Analysts Covering SLRN
1 Year
1 Year Success Rate
0/10 ratings generated profit
1 Year Average Return
-52.87%
assigned a buy rating 4 days ago
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -52.87% per trade.
---